HJ Science Co., Ltd.

华健未来(成都)科技股份有限公司

06132.HK

Develops small-molecule drug candidates for autoimmune, metabolic and oncology diseases, including a TYK2 inhibitor, a GLP-1/GIP agent and a KRAS G12C inhibitor, using an integrated in silico and experimental discovery and development platform; pipeline-focused biotech in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Key long-term agreements
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Preferred shares and fair-value liabilities
• Adverse change after the track record
• Related-party transactions and balances
• Chapter 18A biotech
• Other